INTRODUCTION:

The way a medicine is administered can have a big impact on its effectiveness. Some drugs have an optimum concentration range within which they provide the greatest benefit, and concentrations above or below this range can be toxic or provide no therapeutic benefit at all. On the other hand, the very slow progress in the efficacy of severe disease treatment has suggested a growing need for a multidisciplinary approach to therapeutic delivery to targets in tissues¹.

Advantages of novel drug delivery system

1. Resistance to physical and chemical deterioration.

2. Sustained delivery.

3. Improved tissue macrophages distribution.

4. Stability is improved.

5. Improved pharmacological activity.

6. Protection from toxicity.

7. Bioavailability is improved.

8. Enhancement of solubility².

Polymers have become an integral part of drug delivery systems due to their improved pharmacokinetic properties. They have better circulation time than conventional small drug molecules thus target tissue more specifically. Tremendous use of polymers has been witnessed in the area of polymer therapeutics and Nano medicines³.

Table 1. Types of Polymer

S. No.	Type	Based on origin	Example
1.	Biodegradable	Natural	Gelatin, Chitosan
1.	Biodegradable	Synthetic	Polyethylene, Polylactic acid
2.	Non-Biodegradable	Hydrophilic	HPMC
2.	Non-Biodegradable	Hydrophobic	Ethyl cellulose

Poly (meth) acrylates Polymer:

Polymeric coatings have been applied to solid dosage forms to mask the harsh taste of the medicine, preserve sensitive drug components, control drug release, and/or give the dosage form an aesthetic character⁴. Eudragit is the brand name for a variety of polymethacrylates-based copolymers that are primarily sold by Evonik Industries in Germany. Rohm and Hass GmbH, Darmstadt, first introduced Eudragit in 1953 as an alkaline soluble medicinal coating substance resistant to stomach acid.

Eudragit RL 100:

It's a copolymer made up of quaternary ammonium groups, ethyl acrylate, methyl methacrylate, and a small proportion of methacrylic acid ester. The ammonium groups occur in the form of salts, which allow the polymers to permeate.

Targeted Product Form- Granules Area of Drug Release- Time-controlled release, pH-independent

Characteristics:

· Insoluble

· High permeability

· pH independent swelling

· Customized release profile via RL/RS combination

· Grades in various proportions.

· Appropriate for matrix structures⁵.

Eudragit RS 100:

It's a copolymer made up of quaternary ammonium groups, ethyl acrylates, methyl methacrylate, and a small proportion of methacrylic acid ester. The ammonium groups exist as salts, allowing the polymers to permeate.

Targeted Product Form- Granules Area of Drug Release- Time-controlled release, pH-independent.

Characteristics:

· Insoluble

· High permeability

· pH independent swelling

· Customized release profile via RL/RS combination

· Grades in various proportions.

· Appropriate for matrix structures⁵.

Classification Of Eudragit:

Acryl-EZE MP; Eastacryl 30D; Eudragit; KollicoatMAE 30 D; Kollicoat MAE 30 DP; polymeric methacrylates are commercial names for polymeric methacrylates. They are classified according to their polymeric ratios (Table1) and applications.

Eudragit is classified into four groups:

Eudragit E (soluble below pH5.5) is used for taste masking; Eudragit L and S (soluble above pH 6 and 7, respectively) are used for colon targeting/enteric coating; Eudragit RL and RS (pH-independent solubility) are used for sustained release drug delivery; Eudragit NE and NM (swellable and permeable) are used for sustained release drug delivery⁶. It is widely used as a vehicle for producing solid dispersions and amorphous systems such as microspheres, microparticles, and nanoparticles in order to increase the solubility of low solubility drugs⁷.

Table 2. Classification of Polymethacrylates Based on Polymeric Ratios

Chemical Name	Common Name	Solubility/permeability	Description	Application
Poly(butylmethacrylate, 2-dimethylaminoethyl methacrylate,methyl methacrylate) 1: 2: 1	Eudragit E 12.5	Soluble in gastric fluid to pH 5	Cationic, Yellow in color	Film coating
	Eudragit E 100	Soluble in gastric fluid to pH 5	Cationic, Yellow in color	Film coating
	Eudragit E PO	Soluble in gastric fluid to pH 5	-	Film coating
Poly(methacrylic acid, methy methacrylate) 1 : 2	Eudragit S 12.5 P	Soluble in intestinal fluid to pH 7	Anionic, White free flowing powders	Enteric coating
	Eudragit S 12.5	Soluble in intestinal fluid to pH 7	Anionic, White free flowing powders	Enteric coating
	Eudragit S 100	Soluble in intestinal fluid to pH 7	Anionic, White free flowing powders	Enteric coating
Poly(methyl acrylate, methyl methacrylate, methacrylic acid) 7: 3:1	Eudragit FS 30D	Soluble in intestinal fluid to pH 7	Anionic, Milky white, Low viscosity	Enteric coating
Poly(ethyl acrylate, methyl methacrylate,trimethylammonioethyl methacrylate chloride) 1 : 2 : 0.2	Eudragit RL 100	High permeability	Cationic, non- biodegradable	Sustained release
	Eudragit RL 30D	High permeability	Cationic, non- biodegradable	Sustained release
Poly(ethyl acrylate, methyl methacrylate,trimethylammonioethyl methacrylate chloride) 1 : 2 : 0.	Eudragit RS 12.5	Low permeability	Cationic, non-biodegradable	Sustained release
	Eudragit RS 100	Low permeability	Cationic, non- biodegradable	Sustained release
	Eudragit RS PO	Low permeability	Cationic, non- biodegradable	Sustained release
	Eudragit RS 30 D	Low permeability	Cationic, non- biodegradable	Sustained release
Poly(ethyl acrylate, methyl methacrylate) 2 : 1	Eudragit NE 30 D	Swellable	Cationic, Yellow in color	Sustained release, tablet matrix
Poly(ethyl acrylate, methyl methacrylate) 2 : 1	Eudragit NE 30 D	Swellable	Neutral, Milky white, Low viscosity	Sustained release, tablet matrix
Poly(methacrylic acid, ethyl acrylate) 1 : 1	Eastacryl	Soluble in intestinal fluid from pH 5.5	Cationic	Sustained release, tablet matrix
	Eastacryl 30 D	Soluble in intestinal fluid from pH 5.5	Cationic	Enteric coating
	Kollicoat MAE 30 D	Soluble in intestinal fluid from pH 5.5	Anionic, Milky white, Low viscosity	Enteric coating
	Kollicoat MAE 30 DP	Soluble in intestinal fluid from pH 5.5	-	Enteric coating
	Acryl-EZE	Soluble in intestinal fluid from pH 5.5	-	Enteric coating
	Acryl-EZE MP	Soluble in intestinal fluid from pH 5.5	-	Enteric coating

Pharmaceutical Properties of Eudragit:

Eudragit is the brand name for poly (meth) acrylates in the business. These polymers allow the active ingredient in your solid dose form to work while travelling through the body. The ability to combine multiple polymers allows you to establish the required drug release profile by releasing the medication at the right place, at the right time, and, if necessary, over a specified time period. Other critical features include resistance to external stimuli (moisture) and taste/odor masking to improve patient compliance. Product line offers complete flexibility for specified medication release profiles by providing the greatest performance for enteric, protective, and sustained-release features. Eudragit polymers are copolymers produced from acrylic and methacrylic acid esters, with functional groups determining their physicochemical properties (R). Eudragit polymers come in a wide range of physical configurations (aqueous dispersion, organic solution granules and powders). A distinction is made between 1. Poly (meth) acrylates; salt formation makes them soluble in digestive juices. Eudragit L, S, FS, and E polymers with acidic or alkaline groups allow for pH-dependent active component release⁸.

METHOD OF FORMULAION:

The Ionotropic Gelation Method:

Ionotropic gelation is a simple and low-cost method. Polysaccharides (alginate, gellan, and pectin) are dissolved in water or a weak acidic medium in the ionotropic gelation method⁹. These solutions are then added drop by drop to the solutions containing other counter ions while being constantly stirred. Polysaccharides undergo ionic gelation and precipitate to form spherical particles as a result of complexation between oppositely charged species (microcapsules or beads). Filtration was used to separate the microcapsules, which were then washed with distilled water and dried. Calcium chloride, barium chloride, zinc chloride, copper chloride, cobalt chloride, and pyrophosphate are the counter ions used in the ionotropic gelation method. Some of the most recently used polysaccharides include chitosan, sodium alginate, gellan, and pectin¹⁰.

Solvent Evaporation:

The procedure is performed in a liquid manufacturing vehicle. The microcapsule coating is dispersed in a volatile solvent, which is insoluble in the liquid manufacturing vehicle phase. In the coating polymer solution, a core material to be microencapsulated is dissolved or dispersed. To obtain the appropriate size microcapsule, the core material mixture is dispersed in the liquid manufacturing vehicle phase with agitation. If necessary, the mixture is heated to evaporate the solvent so that the polymer of the core material can disperse in the polymer solution, and the polymer shrinks around the core. Matrix type microcapsules are formed when the core material is dissolved in the coating polymer solution¹¹.

Hot Melt Microencapsulation:

The polymer is melted first, then combined with solid drug particles sieved to less than 50m.The mixture is then suspended in a non-miscible solvent (such as silicone oil), continuously stirred, and heated to 5°C above the polymer's melting point¹². After stabilising the emulsion, it is cooled until the polymer particles solidify. The resulting microspheres are washed with petroleum ether via decantation¹³.

Solvent Extraction Method:

It entails the extraction of the organic solvent from the organic phase.In this case, water miscible organic solvents such as isopropanol are primarily used, and the organic phase is extracted with water. The rate of solvent removal by extraction method is affected by water temperature, emulsion volume to water ratio, and polymer solubility profile¹³.

Spray Drying and Spray Congealing Technique:

These methods rely on the drying of polymer and drug mists in the air. The two processes are referred to as spray drying and spray congealing, depending on whether the solvent is removed or the solution is cooled. The polymer is first dissolved in a suitable volatile organic solvent, such as dichloromethane, acetone, or similar. The solid drug is then dispersed in the polymer solution using high-speed homogenization.This dispersion is then atomized in a hot air stream. Atomization results in the formation of small droplets or fine mists from which the solvent evaporates instantly, resulting in the formation of microspheres with sizes ranging from 1 to 100m. The cyclone separator separates microparticles from hot air, while vacuum drying removes any traces of solvent. Various penicillins are encapsulated using a spray drying process¹⁴.

Phase Separation coacervation Technique:

The drug particles are dispersed in a polymer solution in this method, and an incompatible polymer is added to the system, causing the first polymer to phase separate and engulf the drug particles. The addition of a non-solvent causes the polymer to solidify. This method was used to create poly lactic acid (PLA) microspheres by using butadiene as an incompatible polymer¹⁵

Drug Release Mechanism:

Drug release from oral sustained preparation of eudragit polymers is governed by following principles¹⁶:

· Dissolution

· Diffusion

· Osmotic pressure

· Ion-exchange.

Dissolution

Dissolution from dosage form is frequently the rate-limiting step in drug absorption from the GIT. The process by which a solid substance dissolves in a given solvent, resulting in mass transfer from the solid surface to the liquid phase, is known as dissolution. The reservoir and matrix systems are two types of dissolution controlled dosage forms. Dissolution is the responsible mechanism for controlling drug release in Eudragit S coated 5-ASA. Figure 1 depicts the dissolution release pattern¹⁷.

Fig 1. Dissolution mechanism

Diffusion:

Diffusion is the movement of a substance down a concentration gradient, for example, drug molecules in gastro intestinal fluids diffuse from high concentration to low concentration. Temperature, the density of the diffusing substance, the medium of diffusion, and the concentration gradient are all factors that influence the rate of diffusion. Propranolol HCL was released from the monolithic matrix of Eudragit NE 30 D via a combination of polymer diffusion and pore formation. A combination diffusion/erosion mechanism is used to describe drug release from polymer-wax matrices. Figure 2 depicts the diffusion release pattern¹⁸.

Fig 2. Diffusion release pattern

Osmosis:

The process of moving solvent molecules from a lower concentration to a higher concentration across a semi-permeable membrane is referred to as osmosis. The drug delivery from the osmotic device is regulated by the osmotic pressure created by fluid imbibitions from the external environment into dosage form. The rate of drug release from osmotic dispensing devices is determined by the solute's solubility, molecular weight, and activity coefficient. Figure 3 depicts the osmotic release pattern ¹⁹.

Fig 3: Osmotic release pattern

Ion-exchange:

Because of their physicochemical stability, inert nature, uniform size, spherical shape assisting coating, and equilibrium driven reproducible drug release in the ionic environment, ion exchange resins have been encouraged for use in drug delivery systems. Water-insoluble, polymer-carrying, ionizable functional groups cross-link ion exchange resins. The drug is released from the drug-resin complex via ion exchange in the GI fluid, followed by drug diffusion. In Eudragit RS 30 D-coated theophylline beads, ion exchange was discovered to be a responsible mechanism for controlling polymer permeability as a function of anionic species and concentration²⁰.

Significance of Hydrophobic Polymer:

Literature review on applications of Eudragit suggests that it has been used extensively in the formulation of following types of dosage form vis-à-vis nanoparticals, bilayer tablet, matrix tablet, transdermal patch, vaginal tablets etc as shown in Table 3.

Table 3. Significance of Eudragit Polymers in Drug Delivery System

S. No.	Author Name	Drug Delivery System	Result
1.	R. Pignatello et.al.	Ophthalmic drug delivery	Prepared Polymeric nanoparticles suspensions from inert polymer resins (Eudragit RS100, RS, and RL100, RL) ²¹.
	Shiva Taghe et.al.		The investigation presented to prolong drug release and improve ocular performance, polymeric inserts containing azithromycin-loaded Eudragit® L100 nanoparticles ²².
	Vedanti Salvi et.al.		The investigation presented the development and characterization of a moxifloxacin hydrochloride and ketorolac tromethamine combination loaded Eudragit RL 100 nanosuspension for ocular drug delivery in order to overcome the issues associated with conventional dosage forms ²³.
	Navneet Kumar et.al.		The investigation presented the achieve sustained ocular delivery of levobunolol at the therapeutic level; Eudragit-based nanoparticles of levobunolol were incorporated into a contact lens. The nanoprecipitation methodology was used to create Eudragit nanoparticles of levobunolol using different ratios of Eudragit S100 and polyvinyl alcohol ²⁴.
2.	Rohit Mehta et.al.	Gastrointestinal drug delivery	The investigation presented the wet granulation was used to prepare naproxen matrix tablets using a hydrophobic polymer, such as Eudragit RLPO, RSPO, or a combination of both. The tablets were then dip immersed in different concentrations of Eudragit S-100, a pH-sensitive polymer ²⁵.
	Umar Farooqa et.al.		The investigation presented the oil in water solvent evaporation method was used to successfully prepare Eudragit E 100 and polycaprolactone (PCL) floating microspheres for enhanced gastric retention and drug release. The anti-protozoal drug metronidazole benzoate was used as a model drug ²⁶.
	T. Shams et.al.		Work on single and coaxial electrospraying with Eudragit L100-55 polymer microparticles containing prednisolone as the active pharmaceutical ingredient was presented. Different prednisolone and Eudragit L100-55 compositions were used to create five different formulations with varying polymer: drug ratios ²⁷.
	A. Sanjivani et.al.		The work presented in this study is an attempt to make hollow floating Clarithromycin microspheres for gastro retention using Eudragit polymers prepared via the emulsion solvent diffusion method. Hollow microspheres were created using Eudragit S 100, RS 100, RL 100, L 100, and L 100 55 ²⁸.
3.	Prasanth Viswanadhan Vasantha et.al.	Buccal and Sublingual Drug Delivery	The investigation presented the Salbutamol sulphate patches were created using Eudragit L-100, HPMC, PVA, and Carbopol 934 in various proportions and combinations with PEG-400/PG as plasticizers. For unidirectional drug release, patches were laminated on one side with a water-impermeable backing layer²⁹.
	Anroop B. Nair et.al.		Has optimised rizatriptan's thin mucoadhesive buccal film and assessed the viability of its development as a potential substitute for conventional migraine treatment. Buccal films (FR1–FR10) were created using a polymer blend and a traditional solvent casting method (Proloc, hydroxypropyl methylcellulose and Eudragit RS 100)^30.
	Ashwini Madgulkar et.al.		The investigation presented the Traconazole is practically insoluble in water, and there are large interindividual and intraindividual variations in its oral bioavailability. A mucoadhesive drug delivery system can help to prolong the retention time of a dosage form in the stomach, improving the drug's oral bioavailability³¹.
	U. D. Shivhare et.al.		The study presented a sustained release formulation of Aceclofenac from a mucoadhesive drug delivery system to improve Aceclofenac bioavailability and decrease the frequency of dosage form administration. The solvent evaporation method was used to create aceclofenac-containing mucoadhesive buccal patches. The buccal patches were made with the polymers HPMC E-15 and Eudragit RL 100, both separately and in combination³².
4.	Asgar Ali et.al.	Transdermal Drug Delivery System	The investigation presented the solvent evaporation technique is used to create a transdermal therapeutic system (TTS) of diclofenac diethylamine (DDE). As a penetration enhancer, the matrix diffusion controlled systems used a variety of hydrophilic (polyvinylpyrrolidone K30) and lipophilic (Eudragit RL 100® and Eudragit RS 100®) polymers with dimethyl sulfoxide (DMSO) (0, 5, and 10% w/w) ³³.
	Mitra, A. K. et.al.		The goal of this research is to create Eudragit and polyvinyl pyrrolidone (PVP)-based microneedles (MNs) for improving transdermal drug delivery and to assess their morphology, mechanical strength, and in vitro skin insertion ability. Using the silicone micromolding method, MNs with different weight ratios of Eudragit and PVP were created. The optimised formulations for MN fabrication were Eudragit E100/PVP-K90 (1:2) and Eudragit RS100/PVP-K90 (1:2) ³³.
	Kevin c. Garala et.al.		The study presented blends of hydroxy propyl methyl cellulose (HPMC) and Eudragit S 100 (ES) with triethyl citrate as a plasticizer were used to create monolithic matrix transdermal systems containing tramadol HCl ²⁴.
	B. Anilreddy		The study presented polymers such as ethyl cellulose, poly vinyl alcohol, eudragit RL100, and eudragit L100 were used to create transdermal films of meto prolol tartarate. As a plasticizer, di - n - butylphlthalate was used. The research was done to report on the film forming properties of the polymers used, as well as the in vitro drug release from the prepared monolithic matrices ³⁵.

CONCLUSION:

The current study demonstrates that Eudragit belongs to a class of synthetic polymethacrylate copolymers that are utilised as functional excipients in a variety of medicinal dosage forms. Eudragit polymers can be used to provide time-controlled drug release formulations, enteric formulations for GI targeting, and protective formulations for moisture protection and odor/taste masking. The large variety of applications of eudragit such as in ophthalmic, intestinal, vaginal, gastrointestinal, vaccine, colon, Buccal and sublingual drug delivery system.These multifaceted applications of eudragit polymers in NDDS have made significant contributions to NDDS.

REFERENCES:

1. R.R. Bhagwat and I.S. Vaidhyanovel Drug Delivery Systems: An Overviewijpsr, 2013; 4(3): 970-982. DOI: 10.13040/ijpsr.0975-8232.4(3).970-82.

2. Shaktipal Patil, Amrapali Mhaiskar, Dharmendra MundhadaA Review On Novel Drug Delivery System: A Recent Trend Ijcpcr , 2016;6(2):89-93. DOI: 10.5958/2231–5713

3. Schmaljohann, D. Thermo and pH Responsive Polymers in Drug Delivery. Advanced Drug Delivery Reviews, 2006; 58, 1655-1670. DOI: 10.1016/j.addr.2006.09.020

4. Sadeghi F, shahabi M., Afrasiabi Garekani H. Comparison of physicomechanical properties of films prepared from organic solutions and aqueous dispersion of Eudragit RL,DARU 2011;19 (2) 100-106.

5. Rowe, R. C., Sheskey, P. J., Owen, S. C. In: Rowe, R. C. (Ed) Hand book of Pharmaceutical Excipients. Pharmaceutical press, Great Britain, 2006;916-925; 389-393., 432-433., 132-134.

6. seema thakral, naveen k thakral and dipak k majumdar, eudragit: a technology evaluation, expert opin. drug deliv. 2013; 10(1):131-149. DOI: 10.1517/17425247.2013.736962.

7. Ferreira, I.S. Improvement of the antibacterial activity of daptomycin-loaded polymeric microparticles by Eudragit RL, 100: an assessment by isothermal microcalorimetry. Int. J. Pharm. 2015; 485, 171–182. doi: 10.1016/j.ijpharm.2015.03.016. Epub 2015 Mar 12.

8. Vikrant K Nikam, Kiran B Kotade, Vinayak M Gaware , Ramdas T Dolas, Kiran B Dhamak, Sachin B Somwanshi , Atul N Khadse , Vivekanand A. Kashid Eudragit A Versatile Polymer : A reviewpharmacologyonline 2011; 1: 152-164.

9. Menon Thulasi V., Sajeeth C,I.Formulation of sustained release sodium alginate microbeads of Carvedilol, Research Journal of Pharmacy and Technology,2013;6(4):392-397. DOI: 10.5958/0974-360X

10. Mennini N, Furlanetto S, Mura P. Quality by design approach for developing chitosan- Ca-alginate microspheres for colon delivery of celecoxib-hydroxypropyl-b-cyclodextrin- PVP complex, European journal of Pharmaceutics and Biopharmaceutics, 2012; 80: 67-75. DOI: 10.1016/j.ejpb.2011.08.002

11. Rao B.Chandrasekhara Vidyadhara S, Ragahavendrarao K.V, Prakassh K.Vanitha, Umashankar B., Srilatha.Formulation and evaluation of sustained release methotrexate microcapsules. Research Journal of Pharmacy and Technology, 2011; 4(12):1861-1864.

12. Bobade N.N.,Pande S.D.,Tapar K.K.,Ambelkar P.V.,Malviya S.P..Comprehensive review:controlled release gastro-retentive mucoadhesive microspheres, Research Journal of Pharmacy and Technology,2016;9(3):313-321.

13. Chintale A.G.,Kadam V.S.,Maske K.S., Raur D.B.,Kale S.V.,Rai S.D.Recent advances in microspheres drug delivery systems: A review. Research Journal of Pharmacy and Technology, 2013; 6(3):307-312.

14. Mali Snehal D.,Khochage Swapna R.,Nitalikar Manoj M.,Magdum Chandrakant S. Research Journal of Pharmacy and Technology,2013;6(9):954-961.

15. Kumar S. Vijya, Deka Mnoj Kumar,Bagga Manish, Kala M.Sasi, Sharan Guru. A systematic review on floating drug delivery system, Research Journal of Pharmacy and Technology, 2011;4(1):19-25. DOI: 10.5958/0974-360X

16. Jadhav Ambadas S., Kankudte Ashish D.,Wadikar Jagdish C.,Chintale Ashwini G.,Karde Vaibhav k.,Puri Sachin G.Liquidsolid technique a novel approach to enhance solubility and dissolution rate:A review. Research Journal of Pharmacy and Technology, 2013; 6(8):819-824.

17. Ravikant S.Murkute, R.S. Wanare,Krishna J.Dongre.A review:Recent scenario on osmotic controlled drug delivery system, Research Journal of Pharmacy and Technology,2012;5(5):570-579. DOI: 10.5958/0974-360X

18. Arora Gurpreet,Singh Inderbi,Nagpal Mnju,Arora Sandeep.Recent advances in stimuli induced pulsatile drug delivery systems:Areview, Research Journal of Pharmacy and Technology,2011,4(5):691-703

19. Ritesh Kumar Tiwari, Lalit Singh and Vijay Sharma, Performance Optimization of Sustained Release Arginine Alginate Microbeads with a Natural Polysaccharide, Journal of Pharmaceutical Research International. 2017;17(5): 1-11. DOI:10.9734/JPRI/2017/34305.

20. R. Pignatello, c. Bucolo, G. Puglisi Ocular Tolerability of Eudragit RS1001 and RL1001 Nanosuspensions as Carriers for Ophthalmic Controlled Drug Delivery American Pharmaceutical Association J Pharm Sci2002; 91:2636–2641.

21. Shiva Taghe, Shahla Mirzaeei , Raid G. Alany and Ali Nokhodchi Polymeric Inserts Containing Eudragit® L100 Nanoparticle for Improved Ocular Delivery of Azithromycin , Biomedicines ,2020;8(11):466.

22. Vedanti Salvi, Pravin Pawar Eudragit RL100 Based Moxifloxacin Hydrochloride and Ketorolac Tromethamine Combination Nanoparticulate System for Ocular Drug Delivery Pharmaceutical Nanotechnology2020; 8(2)

23. Navneet Kumar , Rohan Aggarwal and Meenakshi K. Chauhan Extended levobunolol release from Eudragit nanoparticle-laden contact lenses for glaucoma therapy Future Journal of Pharmaceutical Sciences 2020; 6:109.

24. Rohit Mehta Formulation and in vitro evaluation of Eudragit S-100 coated naproxen matrix tablets for colon-targeted drug delivery system J Adv Pharm Technol Res. 2013; 4(1): 31–41.

25. Umar Farooqa , Samiullah Khanb , Shahid Nawaza , Nazar Mohammad Ranjhaa , Malik Salman Haidera , Muhammad Muzamil Khana , Eshwa Darc and Ahmad Nawazd Enhanced gastric retention and drug release via development of novel floating microspheres based on Eudragit E100 and polycaprolactone: synthesis and in vitro evaluation Designed Monomers and Polymers,2017;20(1), 419–433.

26. T. Shams , U. E. Illangakoon1 , M. Parhizkar , A. H. Harker , S. Edirisinghe, M. Orlu and M. Edirisinghe Electrosprayed microparticles for intestinal delivery of prednisolone J. R. Soc. Interface 15: 20180491. 2018:1-10.

27. A. Sanjivani S. Swapnila Development and evaluation of hollow microspheres of clarithromycin as a gastroretentive drug delivery system using eudragit polymers January (2011) International Journal of Pharma and Bio Sciences 2(3):344-358.

28. Prasanth Viswanadhan VasanthaDevelopment and characterization of Eudragit based mucoadhesive buccal patches of salbutamol sulfate Saudi Pharm J. 2011; 19(4): 207–214.

29. Anroop B. Nair , Jigar Shah, Shery Jacob , Bandar E. Al-Dhubiab , Vimal Patel , Nagaraja Sreeharsha , Pottathil Shinu Development of Mucoadhesive Buccal Film for Rizatriptan: In Vitro and In Vivo Evaluation Pharmaceutics,2021;13:728.

30. Ashwini Madgulkar, Shivajirao Kadam, Varsha Pokharkar Development of trilayered mucoadhesive tablet of itraconazole with zero-order release Asian journal of Pharmaceutics, 2008: 57-60.

31. U. D. Shivhare1, P. B. Suruse1, S. S. Varvandkar1 Formulation and Evaluation Of Buccal Patch Containing Aceclofenac. J App Pharm, 2014; 6(1): 65-76.

32. Asgar Ali, Nitin Kumar, Abdul Ahad, Mohd. Aqil and Yasmin Sultana Enhanced delivery of diclofenac diethylamine loaded Eudragit RL 100® transdermal system against inflammationJ Polym Eng. 2015.\

33. Mitra, A. K.; Cholkar, K.; Mahato, R., Mandal, A., Microneedles in Drug Delivery. In Emerging Nanotechnologies for Diagnostics, Drug Delivery and Medical Devices, Eds. Elsevier: boston, 2017; 331-353.

34. Kevin c. Garala, anil j. Shinde, Pratik H. Shah. formulation and in-vitro characterization of monolithic matrix transdermal systems using hpmc/eudragit s 100 polymer blends international journal of Pharmacy and Pharmaceutical Sciences,2009;1(1).

35. B. Anilreddy, In Vitro Characterzatioan and Evaluation of Transdermal Drug Delivery System for Metoprolol Tartarate JPRHC,2020; 2(4)325-329. doi: 10.4103/jphi.JPHI_35_16.

Received on 25.11.2021 Modified on 03.02.2022

Research J. Pharm. and Tech 2023; 16(1):73-78.

DOI: 10.52711/0974-360X.2023.00013